Revance Therapeutics Inc (RVNC)

[floblu14]

Revance says 1st patient enrolled for DaxibotulinumtoxinA study by Fosun Pharma 08:15 RVNC Revance Therapeutic announced that Shanghai Fosun Pharmaceutical Industrial Development, Fosun Pharma Industrial, a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical has initiated Phase 3 trials of DaxibotulinumtoxinA for Injection in China, for the treatment of glabellar lines and cervical dystonia. Both trials enrolled and dosed their first patients in April. China is a fast-growing market for neuromodulators, with an estimated aesthetics and therapeutics opportunity of $318 million in 2021 that is projected to increase to $762 million by 2027, 15.7% CAGR. "The initiation of Phase 3 clinical trials for the treatment of glabellar lines and cervical dystonia marks an important advancement in our international expansion efforts and partnership with Fosun Pharma," said Mark J. Foley, President and Chief Executive Officer at Revance. "Fosun Pharma is a leading pharmaceutical and healthcare company in China and we look forward to continuing our collaboration with them in order to bring our next-generation product to the second largest neuromodulator market in the world." Revance entered into a license agreement with Fosun Pharma Industrial in 2018, whereby Fosun Pharma Industrial received exclusive rights to develop....

Read more at:
https://thefly.com/n.php?id=3290105